Oct 18, 2018 by Brian Orelli, PhDUp 314% in One Day ... and Then Another 58%: How to Find the Next AmarinExpectations plus potential is a recipe for investing success (or disaster).
Oct 12, 2018 by Brian Orelli, PhDHere's Why Verastem Dropped Precipitously TodayConvertible notes issued by the biotech will dilute investors.
Oct 11, 2018 by Brian Orelli, PhDHere's Why Momenta Pharmaceuticals Fell 11.3% on ThursdayInvestors were not impressed with the biotech's R&D day.
Oct 11, 2018 by Brian Orelli, PhDHere's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in SeptemberInvestors are excited about data for its hepatitis B drug.
Oct 11, 2018 by Brian Orelli, PhDHere's Why Viking Therapeutics Skyrocketed 33% in SeptemberSolid phase 2 data has investors excited about the biotech's future.
Oct 11, 2018 by Brian Orelli, PhDHere's Why Sarepta Therapeutics Jumped 17% in SeptemberLifting of a clinical hold continued the momentum.
Oct 9, 2018 by Brian Orelli, PhDHere's Why Geron Plummeted 69% in SeptemberThe biotech's partner said goodbye. Investors cried.
Oct 4, 2018 by Brian Orelli, PhDWhy ImmunoGen, Inc. Fell 10.6% on ThursdayThe volatile biotech has data coming.
Oct 2, 2018 by Brian Orelli, PhDHere's Why AcelRx Pharmaceuticals, Inc. Fell 11.5% on TuesdayTraders toy with the share price ahead of an advisory committee meeting.
Oct 2, 2018 by Brian Orelli, PhDHere's Why Antares Pharma Jumped Higher TodayAn FDA approval for its testosterone drug has investors hitting the buy button.
Oct 1, 2018 by Brian Orelli, PhDHere's Why Insmed Slumped Lower TodayThe FDA gave its new drug a thumbs-up. So why are share prices down?
Sep 26, 2018 by Brian Orelli, PhDGilead Is Undercutting Its Own Drugs: Here's WhyThe biotech is trying to beat the drug pricing system -- or maybe trying to change it for the better.
Sep 25, 2018 by Brian Orelli, PhDWhy AVEO Pharmaceuticals Inc. Rocketed Higher TodayHint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.
Sep 24, 2018 by Brian Orelli, PhDHere's Why AcelRx Pharmaceuticals, Inc. Jumped 16.5% on MondayInvestors rush in ahead of an FDA advisory committee meeting.
Sep 20, 2018 by Brian Orelli, PhDHere's Why Acadia Pharmaceuticals Inc. Spiked Over 26% TodayThe FDA endorses the safety profile of the biotech's Parkinson's disease psychosis drug Nuplazid.
Sep 13, 2018 by Brian Orelli, PhDHere's Why Shares of Progenics Pharmaceuticals Inc. Sank TodayA phase 3 trial failed, but all isn't lost for the biotech.
Sep 11, 2018 by Brian Orelli, PhDWhy Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in AugustThe company's only drug, Exondys 51, is selling well, but investors should be watching the pipeline.
Sep 11, 2018 by Brian Orelli, PhDHere's Why Intercept Pharmaceuticals Jumped 22.7% in AugustIts Ocaliva is selling well enough as investors wait for more clinical trial data next year.
Sep 11, 2018 by Brian Orelli, PhDHere's Why Portola Pharmaceuticals, Inc. Fell 16.6% in AugustUnimpressive launches of two drugs have investors wondering if the biotech can turn things around.
Sep 10, 2018 by Brian Orelli, PhDHere's Why Rigel Pharmaceuticals, Inc. Jumped Over 20% in AugustThe biotech launched Tavalisse during the second quarter. Here's what you need to know.
